Enliven Therapeutics (ELVN) Cash from Financing Activities (2019 - 2026)

Enliven Therapeutics has disclosed Cash from Financing Activities across 8 years of filings, most recently posting $10.1 million for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $10.1 million, up 4196.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $228.7 million (up 430.24% YoY), and the FY2025 annual result was $218.9 million, up 64.36% from the prior year.
• Cash from Financing Activities came in at $10.1 million for Q1 2026 at Enliven Therapeutics, up from $623000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $237.4 million in Q1 2023 to a low of -$2.8 million in Q2 2023.
• The 5-year median for Cash from Financing Activities is $409000.0 (2022), against an average of $35.0 million.
• Peak annual rise in Cash from Financing Activities reached 57954.03% in 2023, while the deepest fall reached 56500.0% in 2023.
• Enliven Therapeutics' Cash from Financing Activities stood at -$2.4 million in 2022, then jumped by 103.79% to $90000.0 in 2023, then surged by 44313.33% to $40.0 million in 2024, then slumped by 98.44% to $623000.0 in 2025, then jumped by 1513.64% to $10.1 million in 2026.
• The last three Cash from Financing Activities figures came in at $10.1 million (Q1 2026), $623000.0 (Q4 2025), and -$368000.0 (Q3 2025), per Business Quant data.